Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) dropped 1.5% on Thursday . The stock traded as low as $57.48 and last traded at $58.84, with a volume of 148,112 shares traded. The stock had previously closed at $59.75.

EGRX has been the topic of several research reports. Mizuho cut shares of Eagle Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $66.00 to $47.00 in a research report on Monday, June 20th. TheStreet upgraded shares of Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 9th. Zacks Investment Research cut shares of Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Friday, July 22nd. Finally, Royal Bank Of Canada reduced their price target on shares of Eagle Pharmaceuticals from $94.00 to $78.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $91.94.

The company has a market capitalization of $922.84 million and a PE ratio of 302.67. The stock’s 50 day moving average price is $52.84 and its 200 day moving average price is $47.93.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.09. The business had revenue of $40.90 million for the quarter, compared to analysts’ expectations of $43.55 million. During the same quarter last year, the business earned ($0.53) EPS. The company’s quarterly revenue was up 581.7% on a year-over-year basis. On average, equities research analysts predict that Eagle Pharmaceuticals Inc. will post $3.21 EPS for the current fiscal year.

In other news, major shareholder Proquest Investments Iv, L.P. sold 24,949 shares of the stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $60.77, for a total transaction of $1,516,150.73. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

An institutional investor recently raised its position in Eagle Pharmaceuticals stock. Ameriprise Financial Inc. raised its position in shares of Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) by 6.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,846 shares of the specialty pharmaceutical company’s stock after buying an additional 1,465 shares during the period. Ameriprise Financial Inc. owned 0.17% of Eagle Pharmaceuticals worth $2,292,000 at the end of the most recent quarter.

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.